Atlas Trials

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Clinical trial NCT04908475 · COMPLETED

Trial details

NCT number
NCT04908475
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Psoriasis
Start date
2021-06-09
Primary completion
2023-04-20
Enrollment
352

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.